JP7166916B2 - シスチンノットスキャフォールドプラットフォーム - Google Patents

シスチンノットスキャフォールドプラットフォーム Download PDF

Info

Publication number
JP7166916B2
JP7166916B2 JP2018513360A JP2018513360A JP7166916B2 JP 7166916 B2 JP7166916 B2 JP 7166916B2 JP 2018513360 A JP2018513360 A JP 2018513360A JP 2018513360 A JP2018513360 A JP 2018513360A JP 7166916 B2 JP7166916 B2 JP 7166916B2
Authority
JP
Japan
Prior art keywords
amino acid
certain embodiments
ckp
seq
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018513360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533912A5 (enExample
JP2018533912A (ja
Inventor
ラミ ハヌーシュ，
ハリニ カルーアラッチ，
アーロン ナイル，
キャメロン ノーランド，
インナン チャン，
リーチュアン チョウ，
シンシン カオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2018533912A publication Critical patent/JP2018533912A/ja
Publication of JP2018533912A5 publication Critical patent/JP2018533912A5/ja
Priority to JP2022096301A priority Critical patent/JP7602514B2/ja
Application granted granted Critical
Publication of JP7166916B2 publication Critical patent/JP7166916B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2018513360A 2015-09-15 2016-09-15 シスチンノットスキャフォールドプラットフォーム Active JP7166916B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022096301A JP7602514B2 (ja) 2015-09-15 2022-06-15 シスチンノットスキャフォールドプラットフォーム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219063P 2015-09-15 2015-09-15
US62/219,063 2015-09-15
PCT/US2016/052012 WO2017049009A1 (en) 2015-09-15 2016-09-15 Cystine knot scaffold platform

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096301A Division JP7602514B2 (ja) 2015-09-15 2022-06-15 シスチンノットスキャフォールドプラットフォーム

Publications (3)

Publication Number Publication Date
JP2018533912A JP2018533912A (ja) 2018-11-22
JP2018533912A5 JP2018533912A5 (enExample) 2019-10-31
JP7166916B2 true JP7166916B2 (ja) 2022-11-08

Family

ID=57068206

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018513360A Active JP7166916B2 (ja) 2015-09-15 2016-09-15 シスチンノットスキャフォールドプラットフォーム
JP2022096301A Active JP7602514B2 (ja) 2015-09-15 2022-06-15 シスチンノットスキャフォールドプラットフォーム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022096301A Active JP7602514B2 (ja) 2015-09-15 2022-06-15 シスチンノットスキャフォールドプラットフォーム

Country Status (22)

Country Link
US (8) US10428125B2 (enExample)
EP (1) EP3350215B1 (enExample)
JP (2) JP7166916B2 (enExample)
KR (1) KR102846388B1 (enExample)
CN (4) CN108026162B (enExample)
AR (1) AR106032A1 (enExample)
AU (2) AU2016323445B2 (enExample)
BR (1) BR112018002263A2 (enExample)
CA (1) CA2996006A1 (enExample)
CL (2) CL2018000668A1 (enExample)
CO (1) CO2018002510A2 (enExample)
CR (1) CR20180169A (enExample)
IL (2) IL294568A (enExample)
MA (1) MA42828A (enExample)
MX (1) MX2018002922A (enExample)
MY (1) MY190552A (enExample)
PE (1) PE20181293A1 (enExample)
PH (1) PH12018500577A1 (enExample)
RU (1) RU2770384C2 (enExample)
TW (1) TWI799366B (enExample)
UA (1) UA125505C2 (enExample)
WO (1) WO2017049009A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
BR112022025227A2 (pt) 2020-06-11 2023-01-03 Genentech Inc Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit
WO2025193946A2 (en) * 2024-03-14 2025-09-18 Genentech, Inc. Peptides binding lrrc15 and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
JP2009511492A (ja) 2005-10-06 2009-03-19 トロフォゲン，インコーポレイテッド Ｖｅｇｆ類縁体および使用方法
US20140039162A1 (en) 2012-01-25 2014-02-06 Swey-Shen Chen Displaying native human IgE neutralizing FceRla-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
JP2014504270A (ja) 2010-11-08 2014-02-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ノッチンペプチドを含む融合タンパク質及びその使用
WO2014033184A1 (en) 2012-08-28 2014-03-06 Novartis Ag Use of a vegf antagonist in treating ocular vascular proliferative diseases
JP2014073129A (ja) 2008-03-27 2014-04-24 Zymogenetics Inc ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
JP2015133978A (ja) 2008-11-03 2015-07-27 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US918814A (en) 1907-10-30 1909-04-20 Handy Mfg Company Funnel.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
CA2320403A1 (en) 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
JP2003528632A (ja) 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
MXPA02011808A (es) 2000-06-01 2003-04-10 Amgen Inc Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos.
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
US7052705B2 (en) 2001-10-03 2006-05-30 Regeneron Pharmaceuticals, Inc. Anti-angiogenic peptides
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
SI1844337T1 (sl) 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
CA2614358A1 (en) 2005-06-29 2007-01-04 Roselli, Patrizia Agonistic and antagonistic peptide mimetics of the vegf alpha-helix binding region for use in therapy
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
US7918814B2 (en) 2006-05-02 2011-04-05 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2008070479A2 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
CA2990445C (en) 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010048588A2 (en) * 2008-10-23 2010-04-29 Massachusetts Institute Of Technology Directed engagement of activating fc receptors
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4 Inc Posterior segment drug delivery
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en) 2009-12-21 2011-08-25 Adrian Raiche Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
WO2011079232A1 (en) 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
US8339139B2 (en) * 2010-01-29 2012-12-25 Infineon Technologies Ag System and method for testing a circuit
US8865741B2 (en) * 2011-02-18 2014-10-21 Asana Biosciences, Llc Aminoindane compounds and use thereof in treating pain
GB201218278D0 (en) * 2012-10-11 2012-11-28 Cyclogenix Ltd Translocating peptide
WO2014063012A1 (en) * 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
JP2009511492A (ja) 2005-10-06 2009-03-19 トロフォゲン，インコーポレイテッド Ｖｅｇｆ類縁体および使用方法
JP2014073129A (ja) 2008-03-27 2014-04-24 Zymogenetics Inc ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
JP2015133978A (ja) 2008-11-03 2015-07-27 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
JP2014504270A (ja) 2010-11-08 2014-02-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ノッチンペプチドを含む融合タンパク質及びその使用
US20140039162A1 (en) 2012-01-25 2014-02-06 Swey-Shen Chen Displaying native human IgE neutralizing FceRla-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2014033184A1 (en) 2012-08-28 2014-03-06 Novartis Ag Use of a vegf antagonist in treating ocular vascular proliferative diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Franziska Maaβ et al.，Cystine-knot peptides targeting cancer-relevant human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).，J. Pept. Sci.，2015年05月10日，Vol.21, No.8，p.651-660，doi: 10.1002/psc.2782
Masa Cemazar et al.，The Structure of a Two-Disulfide Intermediate Assists in Elucidating the Oxidative Folding Pathway of a Cyclic Cystine Knot Protein.，Structure，2008年06月，Vol.16, No.6，p.842-851，doi: 10.1016/j.str.2008.02.023
Michael Reinwarth et al.，Chemical Synthesis, Backbone Cyclization and Oxidative Folding of Cystine-knot Peptides - Promising Scaffolds for Applications in Drug Design.，Molecules，2012年10月24日，Vol.17,，p.12533-12552，doi: 10.3390/molecules171112533
R. Kratzner et al.，Structure of Ecballium elaterium trypsin inhibitor II (EETI-II): a rigid molecular scaffold.，Acta Cryst.，2005年09月，D61, No.9，p.1255-1262，https://doi.org/10.1107/S0907444905021207
Richard H. Kimura et al.，Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low-nanomolar affinity.，PROTEINS，2009年11月01日，Vol.77, No.2，p.359-369，doi: 10.1002/prot.22441
Sunithi Gunasekera et al.，Engineering Stabilized Vascular Endothelial Growth Factor-A Antagonists: Synthesis, Structural Characterization, and Bioactivity of Grafted Analogues of Cyclotides.，J. Med. Chem.，2008年12月25日，Vol.51, No.24，p.7697-7704，doi: 10.1021/jm800704e

Also Published As

Publication number Publication date
CA2996006A1 (en) 2017-03-23
MA42828A (fr) 2018-07-25
CN120248097A (zh) 2025-07-04
CN108026162A (zh) 2018-05-11
BR112018002263A2 (en) 2018-09-18
US20240247034A1 (en) 2024-07-25
US11155586B2 (en) 2021-10-26
CN114805528A (zh) 2022-07-29
US10428125B2 (en) 2019-10-01
WO2017049009A1 (en) 2017-03-23
AU2021204400B2 (en) 2023-02-02
US11078243B2 (en) 2021-08-03
US20200325187A1 (en) 2020-10-15
US20170129927A1 (en) 2017-05-11
EP3350215A1 (en) 2018-07-25
JP2022130481A (ja) 2022-09-06
TW201717993A (zh) 2017-06-01
US20200231636A1 (en) 2020-07-23
AU2016323445A1 (en) 2018-03-01
AU2016323445B2 (en) 2021-04-01
UA125505C2 (uk) 2022-04-13
US20230174596A1 (en) 2023-06-08
KR20180052718A (ko) 2018-05-18
CN114591422A (zh) 2022-06-07
MY190552A (en) 2022-04-27
JP7602514B2 (ja) 2024-12-18
CO2018002510A2 (es) 2018-05-31
CN114591422B (zh) 2025-04-04
RU2770384C2 (ru) 2022-04-15
JP2018533912A (ja) 2018-11-22
TWI799366B (zh) 2023-04-21
US20200115424A1 (en) 2020-04-16
CN108026162B (zh) 2022-04-05
PH12018500577A1 (en) 2018-10-15
IL294568A (en) 2022-09-01
US11407794B2 (en) 2022-08-09
RU2018113442A3 (enExample) 2020-02-17
NZ740218A (en) 2025-05-02
AU2021204400A1 (en) 2021-07-22
EP3350215B1 (en) 2025-12-03
CR20180169A (es) 2018-04-24
HK1253318A1 (zh) 2019-06-14
IL257399A (en) 2018-04-30
US20180291069A1 (en) 2018-10-11
KR102846388B1 (ko) 2025-08-18
AR106032A1 (es) 2017-12-06
CL2018000668A1 (es) 2018-07-20
US10696721B2 (en) 2020-06-30
MX2018002922A (es) 2018-06-07
WO2017049009A8 (en) 2018-02-22
CL2020001781A1 (es) 2020-10-23
IL257399B (en) 2022-08-01
RU2018113442A (ru) 2019-10-16
PE20181293A1 (es) 2018-08-07
US20200140498A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7602514B2 (ja) シスチンノットスキャフォールドプラットフォーム
CN103930437A (zh) Nav1.3和Nav1.7的强效及选择性抑制剂
CN104995207B (zh) β整联蛋白-G蛋白α亚基结合相互作用的抑制剂
JP2019534858A (ja) Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤
HK40072594A (en) Cystine knot scaffold platform
US10562946B2 (en) Chagasin-based scaffold compositions, methods, and uses
HK40067003A (en) Cystine knot scaffold platform
HK1253318B (zh) 胱氨酸结支架平台
HK40067003B (zh) 胱氨酸结支架平台

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220615

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220615

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220628

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220728

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221026

R150 Certificate of patent or registration of utility model

Ref document number: 7166916

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150